Comparison Chart Genmab A/S Nasdaq

Stocks

GMAB

US3723032062

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 23:00:00 12/06/2026 +03			5-day change	1st Jan Change
25.08 ^USD	-0.63%		-0.28%	-18.57%

06-11	Genmab Says Subgroup Data for Follicular Lymphoma Treatment Shows 'Sustained' Efficacy Benefits	MT
06-11	Genmab A/S Presents EPCORE FL-1 Subgroup Data Demonstrating Consistent Efficacy And Safety Results For Epcoritamab In Combination With Rituximab And Lenalidomide R2 Across Relapsed Or Refractory Follicular Lymphoma Patients	CI

Total Return

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes

Compared values

		Sector	Change	5-day change	YTD change	1-year change	5-year change	Capi.	ST	MT	LT
	GENMAB A/S	Bio Therapeutic Drugs	-0.63%	-0.28%	-18.57%	+8.62%	-42.66%	15.4B	-	-	-